Research & Development

Publications & Presentations

Disclaimer
Etripamil is an investigational new drug which is not approved for commercial distribution in the United States. The publications in this section are for educational purposes to discuss clinical data relating to the investigational new drug. Etripamil has not been shown to be safe and effective for FDA approval purposes.

PSVT


Paroxysmal Supraventricular Tachycardia

AFib-RVR


Atrial Fibrillation with Rapid Ventricular Rate

PUBLICATIONS

Phase 3

Randomized Controlled Trial

Self-administered Intranasal Etripamil Using a Symptom-prompted, Repeat-dose Regimen for Atrioventricular-nodal-dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial

The Lancet (Jul 2023)
Read the Plain Language Summary|Listen to the podcast

Randomized Controlled Trial

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

American Heart Association (Dec 2022)

Randomized Controlled Trial

Rationale For and Design of a Multicenter, Placebo-controlled, Phase 3 Study to Assess Efficacy and Safety of Intranasal Etripamil for the Conversion of Paroxysmal Supraventricular Tachycardia

American Heart Journal (Jun 2022)

Open-label clinical studies

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open-label Study – ScienceDirect

The Journal of The American College of Cardiology (Mar 2024)

Open-label clinical studies

Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings

American Heart Journal (Jan 2024)

Open-label clinical studies

Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Journal of the American Heart Association (Sep 2023)

Phase 2

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.

Journal of the American College of Cardiology (Apr 2018)

PK/PD

Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast‐Acting, Nondihydropyridine Calcium Channel Blocker (wiley.com).

Clinical Pharmacology in Drug Development. (Feb 2024)

Preclinical Safety Evaluation of Etripamil Nasal Spray in Cynomolgus Macaques (Macaca fascicularis) to Assess for Safety in Patients With Paroxysmal Supraventricular Tachycardia.

International Journal of Toxicology (July 2024)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Etripamil in Healthy Japanese and Non-Japanese Adults

Journal of the American College of Cardiology (jacc.org) (Mar 2022)

HEOR/RWE

Catheter ablation for supraventricular tachycardia and health resource utilization and expenditures: A propensity-matched cohort study – ScienceDirect

International Journal of Cardiology (May 2024)

Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia inthe United States.

Journal of Cardiovascular Electrophysiology (Aug 2021)

Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

American Heart Journal (Mar 2021)

Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

Journal of the American Heart Association (Sep 2020)

Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.

American Journal of Cardiology. (Jan 2020)

PRESENTATIONS

Frequency and Patterns of Paroxysmal Supraventricular Tachycardia Episodes Among Patients Opting For Acute Drug Treatment: Analysis of the NODE-303 Open-Label Etripamil Trial

American Heart Association (November 2024)

Healthcare Resource Utilization (HRU) Among Patients with Paroxysmal Supraventricular Tachycardia (PSVT)

AMCP Nexus 2024 (October 2024)

Healthcare Resource Utilization After Etripamil Treatment to Terminate Paroxysmal Supraventricular Tachycardia: A Pooled Analysis of Clinical Trials

American College of Emergency Physicians (October 2024)

Quality of life measures with etripamil self-administration for acute episodes of paroxysmal supraventricular tachycardia in a medically unsupervised setting: patient-reported outcomes from NODE-303

European Society of Cardiology (August 2024)

Self-Administered Etripamil Nasal Spray Rapidly Terminated Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT): Analysis of Open-Label Treatment in the RAPID Study

Heart Rhythm Society (May 2024)

Analysis of Healthcare Resource Utilization in the NODE-303 Trial to Terminate Paroxysmal Supraventricular Tachycardia Episodes

ISPOR (April 2024)

Assessing the Real-World Impact of Paroxysmal Supraventricular Tachycardia on Quality of Life: A Longitudinal Study with a Focus on Anxiety Burden.

Preventative Cardiovascular Nurses Association. (April 2024)

NODE 303: Multi-Center, Multi-National, Open-Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.

American College of Cardiology (2024)

Characterising Paroxysmal Supraventricular Tachycardia Episodes by Patient-Perceived Episode Duration, Symptoms and Severity: Longitudinal Patient-Reported Outcomes

EHRA (Apr 2024)

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients with Supraventricular Tachycardia

ISPOR (May 2023)

Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

EHRA (Apr 2023)

Identifying the Human Blood Esterases Responsible for Metabolism of Etripamil, a Fast-Acting Calcium Channel Blocker Developed to Treat Paroxysmal Supraventricular Tachycardia

Society of Toxicology (Mar 2024)

Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study

American Heart Association (Nov 2022)

HRS 22: Long-Term Outcomes of the NODE-302 Study | Dr James Ip

Heart Rhythm Society (May 2022)

Etripamil Nasal Spray for Acute Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Heart Rhythm Society (May 2022)

Analysis of Clinical Outcomes in the NODE-301 Trial

American College of Cardiology (Apr 2022)

Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

Heart Rhythm Society (Apr 2022)

Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

American Heart Association (Nov 2021)